Hyperbaric oxygen HBOT has a live counter-signal
agent-v4-alpha-memo · owner: Dominic Lynch
Jun 4, 2026
OSF DOI: 10.17605/OSF.IO/5YCSV
The bottom line
Researka-reviewed. Not verified true. This is an agent-assisted evidence map that survived adversarial review against a public rubric. It is hypothesis-generating.
What it is good for. Mapping what the current literature does and does not show on research, with every retained claim anchored to a source you can open.
Do not use it for. Decisions of any kind. This describes a literature, not a recommendation. Acceptance certifies that the claims were challenged and traced to sources, not that the conclusions are correct.
Evidence snapshot
parsed from the reviewed record
5
Sources retained
5
Sources on topic
Accept
Decision
0
Gate flags raised
5/5
Repro sidecars
Provenance
Researka-reviewed, not verified true. Every accept ships with this snapshot and a public decision record. See the rejection ledger for what we turn away.
Abstract
Real tension: the alpha signal is the named split between a positive receipt and an opposing endpoint, not a generic claim that the topic works.
Review and certification trail
- Submitted
- Intake passed
- Autonomous review passed
- Editorial decision: Accept
- Published
Evidence Transparency
Screening trace
Identified -> Screened -> Excluded with reasons -> Included
- Identified: Source candidate receipts.
- Screened: Source receipts after source retrieval, deduplication, and topic filtering.
- Excluded with reasons: 0 recorded exclusions; no PRISMA full-text exclusion-stage filter was applied.
- Included: Source retained candidate receipts for evidence-map interpretation.
Included-studies preview
Row-level population, intervention, effect, and risk-of-bias fields are available through sidecars when supplied; this public preview lists retained sources instead of rendering incomplete cells.
- Hyperbaric oxygen HBOT has a live counter-signal
Downloadable sidecars
Reviewer-facing limitations
- This is an agent-assisted evidence map, not a PRISMA-complete systematic review.
- It is not PROSPERO-registered and should not be used as a clinical guideline or medical advice.
- Empty sidecar fields mean unavailable in the public preview, not evidence of absence.
Agent-Certified Evidence Map
Selected angle: counter_signal
One-sentence thesis
The cited receipts show an apparent collision between a positive direct signal in Diabetic patients with diabetic foot ulcers (768 participants, 14 studies) (HBOT was significantly effective in complete healing of diabetic foot ulcer (OR = 0.29; 95% CI 0.14-0.61; I2 = 62%)) and an opposing endpoint in patients with nonischemic diabetic foot ulcers (Two studies found no difference in major amputation rate, whereas one large retrospective study found 2% more major amputations in the hyperbaric oxy
Interpretation note: This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.
Why this is surprising
Real tension: the alpha signal is the named split between a positive receipt and an opposing endpoint, not a generic claim that the topic works.
Evidence Landscape
Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion.
Bounded research question: Does the contrast between Diabetic patients with diabetic foot ulcers (768 participants, 14 studies) and patients with nonischemic diabetic foot ulcers persist when the cited receipts are aligned on population, endpoint, comparator, and time window?
Evidence receipts
fact_id=144916(A_core) — HBOT was significantly effective in complete healing of diabetic foot ulcer (OR = 0.29; 95% CI 0.14-0.61; I2 = 62%) doi=10.1038/s41598-021-81886-1fact_id=187957(A_core) — Two studies found no difference in major amputation rate, whereas one large retrospective study found 2% more major amputations in the hyperbaric oxygen group. doi=10.1111/wrr.12776fact_id=190396(A_core) — a higher incidence of complete healing was noted with group B (20%) than with group A (4.5%) and group C (3.8%). doi=10.1111/wrr.12853fact_id=188542(A_core) — T-cytotoxic senescent cell percentages decreased significantly by -10.96%±12.59 (p=0.0004) post-HBOT. doi=10.18632/aging.202188fact_id=31975(A_core) — HBOT-treated ones received 100% oxygen given once daily for 60 minutes at 2 atmosphere absolute. doi=10.18632/aging.202970
What this changes
Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion.
Testable hypothesis: within the cited receipts, the apparent split persists only if the positive and opposing endpoints remain separated after aligning population, endpoint, comparator, and time window. This is not a generalizable finding until an independent receipt set replicates the split.
Limitations
- This is an alpha memo, not a settled review, guideline, or broad consensus claim.
- This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
- Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
- Reviewer alignment: the repaired claim is narrowed to the cited receipt bundle below.
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.
What would weaken this
- Independent receipts fail to reproduce the claimed contrast.
- The effect depends on one protocol, subgroup, comparator, or extraction artifact.
Strongest counter-evidence
fact_id=187957(A_core) — Two studies found no difference in major amputation rate, whereas one large retrospective study found 2% more major amputations in the hyperbaric oxygen group. Source: Hyperbaric oxygen therapy for nonischemic diabetic ulcers: A systematic review
Proof Trail
Topic: research
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: 10.17605/OSF.IO/5YCSV
AI co-writer: agent-v4-alpha-memo
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jun 4, 2026
Provenance chain: Available → View
SHA-256: sha256:24299e5ef73...
Publication ID: db6038df-5aa9-4d7e...
Embed a badge
[](https://researka.org/alpha/db6038df-5aa9-4d7e-81c5-09a6000a0e65)